faculty_name,faculty_email,publication_type,title,journal,year,doi,url,file_created
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors.,Seminars in Arthritis and Rheumatism,2025,10.1016/j.semarthrit.2025.152769,https://experts.mcmaster.ca/display/publication3595886,2025-07-27T15:11:30.475980
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial.,Nature Medicine,2025,10.1038/s41591-025-03628-4,https://experts.mcmaster.ca/display/publication3566497,2025-07-27T15:11:30.475985
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,An international guideline training and certification programme.,Bulletin of the World Health Organization,2025,10.2471/BLT.24.291587,https://experts.mcmaster.ca/display/publication3568413,2025-07-27T15:11:30.475987
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Enhancing health equity considerations in guidelines: health equity extension of the GIN-McMaster Guideline Development Checklist.,EClinicalMedicine,2025,10.1016/j.eclinm.2025.103135,https://experts.mcmaster.ca/display/publication3566546,2025-07-27T15:11:30.475988
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary.,Blood Advances,2025,10.1182/bloodadvances.2024014219,https://experts.mcmaster.ca/display/publication3480407,2025-07-27T15:11:30.475989
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Defining decision thresholds for judgments on health benefits and harms using the grading of recommendations assessment, development, and evaluation (GRADE) evidence to decision (EtD) frameworks: a randomized methodological study (GRADE-THRESHOLD).",Journal of Clinical Epidemiology,2025,10.1016/j.jclinepi.2024.111639,https://experts.mcmaster.ca/display/publication3502137,2025-07-27T15:11:30.475990
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic review and evidence map to inform clinical practice guidelines.,BMJ Open,2025,10.1136/bmjopen-2024-088267,https://experts.mcmaster.ca/display/publication3526920,2025-07-27T15:11:30.475991
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation.,The BMJ,2024,10.1136/bmj-2024-079183,https://experts.mcmaster.ca/display/publication3490098,2025-07-27T15:11:30.475992
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"GRADE Guidance 39: Using GRADE-ADOLOPMENT to adopt, adapt or create contextualized recommendations from source guidelines and evidence syntheses",Journal of Clinical Epidemiology,2024,10.1016/j.jclinepi.2024.111494,https://experts.mcmaster.ca/display/publication3460398,2025-07-27T15:11:30.475993
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Core outcome set developers should consider and specify the level of granularity of outcome domains,Journal of Clinical Epidemiology,2024,10.1016/j.jclinepi.2024.111307,https://experts.mcmaster.ca/display/publication3402819,2025-07-27T15:11:30.475994
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Representation of published core outcome sets in practice guidelines,Journal of Clinical Epidemiology,2024,10.1016/j.jclinepi.2024.111311,https://experts.mcmaster.ca/display/publication3402820,2025-07-27T15:11:30.475995
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,The INGUIDE International Guideline Training and Certification Programme,Clinical and Public Health Guidelines,2024,10.1002/gin2.12008,https://experts.mcmaster.ca/display/publication3410597,2025-07-27T15:11:30.475996
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing,Blood Advances,2023,10.1182/bloodadvances.2023010177,https://experts.mcmaster.ca/display/publication3234482,2025-07-27T15:11:30.475997
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Antibiotic prescribing guideline recommendations in COVID-19: a systematic survey,EClinicalMedicine,2023,10.1016/j.eclinm.2023.102257,https://experts.mcmaster.ca/display/publication3300738,2025-07-27T15:11:30.475998
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Proposed triggers for retiring a living systematic review,BMJ Evidence-Based Medicine,2023,10.1136/bmjebm-2022-112100,https://experts.mcmaster.ca/display/publication2980661,2025-07-27T15:11:30.475999
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Prospective collaborative recommendation development: a novel model for more timely and trustworthy guidelines,Journal of Clinical Epidemiology,2023,10.1016/j.jclinepi.2023.08.015,https://experts.mcmaster.ca/display/publication3299117,2025-07-27T15:11:30.476000
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance,BMJ Evidence-Based Medicine,2023,10.1136/bmjebm-2022-111962,https://experts.mcmaster.ca/display/publication2184076,2025-07-27T15:11:30.476001
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Adv. 2021;5(20):3951-3959.",Blood Advances,2023,10.1182/bloodadvances.2022008060,https://experts.mcmaster.ca/display/publication3463978,2025-07-27T15:11:30.476002
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal,BMJ Evidence-Based Medicine,2022,10.1136/bmjebm-2021-111866,https://experts.mcmaster.ca/display/publication2184075,2025-07-27T15:11:30.476003
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions,Journal of Clinical Epidemiology,2022,10.1016/j.jclinepi.2022.07.015,https://experts.mcmaster.ca/display/publication2435789,2025-07-27T15:11:30.476004
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients,Blood Advances,2022,10.1182/bloodadvances.2022007940,https://experts.mcmaster.ca/display/publication2294216,2025-07-27T15:11:30.476005
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients,Blood Advances,2022,10.1182/bloodadvances.2022007561,https://experts.mcmaster.ca/display/publication2187653,2025-07-27T15:11:30.476006
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,A Framework for the Development of Living Practice Guidelines in Health Care,ACP journal club,2022,10.7326/m22-0514,https://experts.mcmaster.ca/display/publication2378085,2025-07-27T15:11:30.476007
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,An evaluation of the COVID-19 recommendation map identified diverging clinical and public health guidance,Journal of Clinical Epidemiology,2022,10.1016/j.jclinepi.2022.03.008,https://experts.mcmaster.ca/display/publication2188998,2025-07-27T15:11:30.476008
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Standardized wording to improve efficiency and clarity of GRADE EtD frameworks in health guidelines,Journal of Clinical Epidemiology,2022,10.1016/j.jclinepi.2022.01.004,https://experts.mcmaster.ca/display/publication2181049,2025-07-27T15:11:30.476009
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"In-Hospital Macro-, Meso-, and Micro-Drivers and Interventions for Antibiotic Use and Resistance: A Rapid Evidence Synthesis of Data from Canada and Other OECD Countries",Canadian Journal of Infectious Diseases and Medical Microbiology,2022,10.1155/2022/5630361,https://experts.mcmaster.ca/display/publication2190637,2025-07-27T15:11:30.476010
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,New methods facilitated the process of prioritizing questions and health outcomes in guideline development,Journal of Clinical Epidemiology,2022,10.1016/j.jclinepi.2021.11.031,https://experts.mcmaster.ca/display/publication2157242,2025-07-27T15:11:30.476011
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis,Blood Advances,2022,10.1182/bloodadvances.2021005945,https://experts.mcmaster.ca/display/publication2145612,2025-07-27T15:11:30.476012
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Cost-effectiveness of diagnostic strategies for venous thromboembolism: a systematic review,Blood Advances,2022,10.1182/bloodadvances.2020003576,https://experts.mcmaster.ca/display/publication2136278,2025-07-27T15:11:30.476013
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations,Journal of Clinical Epidemiology,2022,10.1016/j.jclinepi.2021.09.028,https://experts.mcmaster.ca/display/publication2142168,2025-07-27T15:11:30.476014
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"A modeling approach to derive baseline risk estimates for GRADE recommendations: Concepts, development, and results of its application to the American Society of Hematology 2019 guidelines on prevention of venous thromboembolism in surgical hospitalized patients",Journal of Clinical Epidemiology,2021,10.1016/j.jclinepi.2021.07.010,https://experts.mcmaster.ca/display/publication2026264,2025-07-27T15:11:30.476015
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines,Blood Advances,2021,10.1182/bloodadvances.2020003577,https://experts.mcmaster.ca/display/publication2126643,2025-07-27T15:11:30.476016
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients,Blood Advances,2021,10.1182/bloodadvances.2021005493,https://experts.mcmaster.ca/display/publication2123451,2025-07-27T15:11:30.476017
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines,Journal of Clinical Epidemiology,2021,10.1016/j.jclinepi.2021.04.016,https://experts.mcmaster.ca/display/publication1969571,2025-07-27T15:11:30.476018
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Clinical practice guideline for transcatheter versus surgical valve replacement in patients with severe aortic stenosis in Latin America,Heart,2021,10.1136/heartjnl-2021-319489,https://experts.mcmaster.ca/display/publication1981812,2025-07-27T15:11:30.476019
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,GRADE notes: How to use GRADE when there is “no” evidence? A case study of the expert evidence approach,Journal of Clinical Epidemiology,2021,10.1016/j.jclinepi.2021.02.026,https://experts.mcmaster.ca/display/publication1961667,2025-07-27T15:11:30.476020
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases,Journal of Rheumatology,2021,10.3899/jrheum.210288,https://experts.mcmaster.ca/display/publication1969243,2025-07-27T15:11:30.476021
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Systematic review of treatment gaps in oral anticoagulant use in atrial fibrillation,Thrombosis Update,2021,10.1016/j.tru.2021.100053,https://experts.mcmaster.ca/display/publication1975390,2025-07-27T15:11:30.476022
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Recommendation mapping of the World Health Organization's guidelines on tuberculosis: A new approach to digitizing and presenting recommendations,Journal of Clinical Epidemiology,2021,10.1016/j.jclinepi.2021.02.009,https://experts.mcmaster.ca/display/publication1965029,2025-07-27T15:11:30.476023
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation,European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy,2021,10.1093/ehjcvp/pvaa052,https://experts.mcmaster.ca/display/publication1910784,2025-07-27T15:11:30.476024
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Coronavirus Disease 2019 and Antimicrobial Resistance: Parallel and Interacting Health Emergencies,Clinical Infectious Diseases,2021,10.1093/cid/ciaa773,https://experts.mcmaster.ca/display/publication1915841,2025-07-27T15:11:30.476025
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism,Blood Advances,2021,10.1182/bloodadvances.2020002398,https://experts.mcmaster.ca/display/publication1967672,2025-07-27T15:11:30.476026
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Methodological assessment of Mexican Clinical Practice Guidelines:GRADEframework adherence and critical appraisal,Journal of Evaluation in Clinical Practice,2021,10.1111/jep.13447,https://experts.mcmaster.ca/display/publication1922959,2025-07-27T15:11:30.476027
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,The quality of subgroup analyses in chronic pain randomized controlled trials: a methodological review,Korean Journal of Pain,2021,10.3344/kjp.2021.34.2.139,https://experts.mcmaster.ca/display/publication1964978,2025-07-27T15:11:30.476028
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Control of Severe, Life-Threatening External Bleeding in the Out-of-Hospital Setting: A Systematic Review",Prehospital Emergency Care,2021,10.1080/10903127.2020.1743801,https://experts.mcmaster.ca/display/publication1701903,2025-07-27T15:11:30.476029
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19,Blood Advances,2021,10.1182/bloodadvances.2020003763,https://experts.mcmaster.ca/display/publication1959291,2025-07-27T15:11:30.476030
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Development and use of health outcome descriptors: a guideline development case study,Health and Quality of Life Outcomes,2020,10.1186/s12955-020-01338-8,https://experts.mcmaster.ca/display/publication1914476,2025-07-27T15:11:30.476031
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Erratum to “Controversy and debate series on core outcome sets. Paper 3:debate on paper 1 from the perspective of GRADE [Grading of Recommendations Assessment, Development and Evaluation]” [Journal of Clinical Epidemiology 125C (2020) 216-221]",Journal of Clinical Epidemiology,2020,10.1016/j.jclinepi.2020.09.014,https://experts.mcmaster.ca/display/publication1934708,2025-07-27T15:11:30.476032
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses,Blood Advances,2020,10.1182/bloodadvances.2020002963,https://experts.mcmaster.ca/display/publication1936271,2025-07-27T15:11:30.476033
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,2020 International Consensus on First Aid Science With Treatment Recommendations.,Resuscitation,2020,10.1161/CIR.0000000000000897,https://experts.mcmaster.ca/display/publication3427149,2025-07-27T15:11:30.476034
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism,Blood Advances,2020,10.1182/bloodadvances.2020001830,https://experts.mcmaster.ca/display/publication1928128,2025-07-27T15:11:30.476035
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Scope of Outcomes in Trials and Observational Studies of Interventions Targeting Medication Adherence in Rheumatic Conditions: A Systematic Review,Journal of Rheumatology,2020,10.3899/jrheum.190726,https://experts.mcmaster.ca/display/publication1684524,2025-07-27T15:11:30.476036
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Controversy and Debate Series on Core Outcome Sets: The SOLAR (Standardized Outcomes Linking Across StakeholdeRs) system and hub and spokes model for direct core outcome measures in health care and its relation to GRADE,Journal of Clinical Epidemiology,2020,10.1016/j.jclinepi.2020.05.007,https://experts.mcmaster.ca/display/publication1910853,2025-07-27T15:11:30.476037
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Ventilation Techniques and Risk for Transmission of Coronavirus Disease, Including COVID-19",ACP journal club,2020,10.7326/m20-2306,https://experts.mcmaster.ca/display/publication1904194,2025-07-27T15:11:30.476038
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Pharmacologic thromboprophylaxis in adult patients undergoing neurosurgical interventions for preventing venous thromboembolism,Blood Advances,2020,10.1182/bloodadvances.2020002195,https://experts.mcmaster.ca/display/publication1915912,2025-07-27T15:11:30.476039
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Systematic review and meta-analysis of outcomes in patients with suspected deep vein thrombosis,Blood Advances,2020,10.1182/bloodadvances.2020001558,https://experts.mcmaster.ca/display/publication1915911,2025-07-27T15:11:30.476040
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry),Blood Advances,2020,10.1182/bloodadvances.2019001373,https://experts.mcmaster.ca/display/publication1914337,2025-07-27T15:11:30.476041
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Diagnosis of deep vein thrombosis of the upper extremity: a systematic review and meta-analysis of test accuracy,Blood Advances,2020,10.1182/bloodadvances.2019001409,https://experts.mcmaster.ca/display/publication1914474,2025-07-27T15:11:30.476042
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences",Blood Advances,2020,10.1182/bloodadvances.2020001768,https://experts.mcmaster.ca/display/publication1910855,2025-07-27T15:11:30.476043
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,A user guide to the American Society of Hematology clinical practice guidelines,Blood Advances,2020,10.1182/bloodadvances.2020001755,https://experts.mcmaster.ca/display/publication1895933,2025-07-27T15:11:30.476044
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines,Blood Advances,2020,10.1182/bloodadvances.2019000840,https://experts.mcmaster.ca/display/publication1703686,2025-07-27T15:11:30.476045
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Diagnosis of deep vein thrombosis of the lower extremity: a systematic review and meta-analysis of test accuracy,Blood Advances,2020,10.1182/bloodadvances.2019000960,https://experts.mcmaster.ca/display/publication1701960,2025-07-27T15:11:30.476046
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis,Blood Advances,2020,10.1182/bloodadvances.2020001513,https://experts.mcmaster.ca/display/publication1703687,2025-07-27T15:11:30.476047
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Patient values and preferences regarding VTE disease: a systematic review to inform American Society of Hematology guidelines,Blood Advances,2020,10.1182/bloodadvances.2019000462,https://experts.mcmaster.ca/display/publication1697057,2025-07-27T15:11:30.476048
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis,Blood Advances,2020,10.1182/bloodadvances.2019001223,https://experts.mcmaster.ca/display/publication1690038,2025-07-27T15:11:30.476049
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry,American Journal of Cardiology,2020,10.1016/j.amjcard.2019.10.047,https://experts.mcmaster.ca/display/publication1682099,2025-07-27T15:11:30.476050
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,The eCOVID-19 living recommendations map and gateway to contextualisation,Cochrane Database of Systematic Reviews,2020,,https://experts.mcmaster.ca/display/publication2187515,2025-07-27T15:11:30.476051
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,A meta-epidemiological study of subgroup analyses in cochrane systematic reviews of atrial fibrillation,Systematic Reviews,2019,10.1186/s13643-019-1152-z,https://experts.mcmaster.ca/display/publication1673077,2025-07-27T15:11:30.476052
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Ethical issues in competing clinical trials,Contemporary Clinical Trials Communications,2019,10.1016/j.conctc.2019.100352,https://experts.mcmaster.ca/display/publication1639863,2025-07-27T15:11:30.476053
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Structured decision-making drives guidelines panels' recommendations “for” but not “against” health interventions,Journal of Clinical Epidemiology,2019,10.1016/j.jclinepi.2019.02.009,https://experts.mcmaster.ca/display/publication1629424,2025-07-27T15:11:30.476054
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation,Blood Advances,2019,10.1182/bloodadvances.2019000067,https://experts.mcmaster.ca/display/publication1642005,2025-07-27T15:11:30.476055
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,The Canadian Community Utilization of Stroke Prevention Study in Atrial Fibrillation in the Emergency Department (C-CUSP ED),Annals of Emergency Medicine,2019,10.1016/j.annemergmed.2018.09.001,https://experts.mcmaster.ca/display/publication1612311,2025-07-27T15:11:30.476056
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis,Blood Advances,2019,10.1182/bloodadvances.2018025163,https://experts.mcmaster.ca/display/publication1634239,2025-07-27T15:11:30.476057
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis,Blood Advances,2019,10.1182/bloodadvances.2018024133,https://experts.mcmaster.ca/display/publication1620968,2025-07-27T15:11:30.476058
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Evidence to Decision framework provides a structured “roadmap” for making GRADE guidelines recommendations,Journal of Clinical Epidemiology,2018,10.1016/j.jclinepi.2018.09.007,https://experts.mcmaster.ca/display/publication1595844,2025-07-27T15:11:30.476059
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol,Trials,2018,10.1186/s13063-018-2565-z,https://experts.mcmaster.ca/display/publication1513623,2025-07-27T15:11:30.476060
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy,Blood Advances,2018,10.1182/bloodadvances.2018024893,https://experts.mcmaster.ca/display/publication1610397,2025-07-27T15:11:30.476061
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients,Blood Advances,2018,10.1182/bloodadvances.2018022954,https://experts.mcmaster.ca/display/publication1611341,2025-07-27T15:11:30.476062
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries,European Journal of Internal Medicine,2018,10.1016/j.ejim.2018.05.016,https://experts.mcmaster.ca/display/publication1535055,2025-07-27T15:11:30.476063
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey),American Journal of Cardiology,2018,10.1016/j.amjcard.2018.04.053,https://experts.mcmaster.ca/display/publication1561756,2025-07-27T15:11:30.476064
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Improving medication adherence in patients with cardiovascular disease: a systematic review,Heart,2018,10.1136/heartjnl-2017-312571,https://experts.mcmaster.ca/display/publication1514131,2025-07-27T15:11:30.476065
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,P4799When are atrial fibrillation patients at risk to discontinue anticoagulation treatment? Results from the GLORIA-AF Registry,European Heart Journal,2018,10.1093/eurheartj/ehy563.p4799,https://experts.mcmaster.ca/display/publication1977313,2025-07-27T15:11:30.476066
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Development, Testing, and Implementation of a Training Curriculum for
                        Nonphysician Health Workers to Reduce Cardiovascular Disease",Global Heart,2018,10.1016/j.gheart.2017.11.002,https://experts.mcmaster.ca/display/publication1490113,2025-07-27T15:11:30.476067
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,The influence of progression of atrial fibrillation on quality of life: a report from the Euro Heart Survey,Europace,2018,10.1093/europace/eux217,https://experts.mcmaster.ca/display/publication1465291,2025-07-27T15:11:30.476068
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Developing consensus measures for global programs: lessons from the Global Alliance for Chronic Diseases Hypertension research program,Globalization and Health,2017,10.1186/s12992-017-0242-8,https://experts.mcmaster.ca/display/publication459675,2025-07-27T15:11:30.476069
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Erratum to: Effectiveness and content analysis of interventions to enhance medication adherence in hypertension: a systematic review and meta-analysis protocol,Systematic Reviews,2017,10.1186/s13643-017-0429-3,https://experts.mcmaster.ca/display/publication459676,2025-07-27T15:11:30.476070
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Symptomatic atrial fibrillation and risk of cardiovascular events: data from the Euro Heart Survey,Europace,2017,10.1093/europace/eux205,https://experts.mcmaster.ca/display/publication1474054,2025-07-27T15:11:30.476071
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Congruence between patient characteristics and interventions may partly explain medication adherence intervention effectiveness: an analysis of 190 randomized controlled trials from a Cochrane systematic review,Journal of Clinical Epidemiology,2017,10.1016/j.jclinepi.2017.07.011,https://experts.mcmaster.ca/display/publication1432984,2025-07-27T15:11:30.476072
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Effectiveness and content analysis of interventions to enhance medication adherence and blood pressure control in hypertension: A systematic review and meta-analysis,Psychology and Health,2017,10.1080/08870446.2016.1273356,https://experts.mcmaster.ca/display/publication459677,2025-07-27T15:11:30.476073
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation,Journal of the American College of Cardiology,2017,10.1016/j.jacc.2017.07.793,https://experts.mcmaster.ca/display/publication1459062,2025-07-27T15:11:30.476074
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,The role of pragmatism in explaining heterogeneity in meta-analyses of randomised trials: a protocol for a cross-sectional methodological review,BMJ Open,2017,10.1136/bmjopen-2017-017887,https://experts.mcmaster.ca/display/publication1455745,2025-07-27T15:11:30.476075
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,5769Changes in thromboembolic risk profile and antithrombotic therapy use over a decade: a comparison of Euro Heart Survey on AF and EURObservational research programme AF pilot registry,European Heart Journal,2017,10.1093/eurheartj/ehx493.5769,https://experts.mcmaster.ca/display/publication3463993,2025-07-27T15:11:30.476076
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,P1380Gender differences in the progression of atrial fibrillation in low-risk paroxysmal AF patients with hypertension: the role of left ventricular hypertrophy,Europace,2017,10.1093/ehjci/eux158.008,https://experts.mcmaster.ca/display/publication3463994,2025-07-27T15:11:30.476077
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,P283The influence of progression of atrial fibrillation on quality of life: a report from the euro heart survey,Europace,2017,10.1093/ehjci/eux141.011,https://experts.mcmaster.ca/display/publication3463995,2025-07-27T15:11:30.476078
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,MP09: Canadian Community Utilization of Stroke Prevention Pilot Study-Emergency Department (C-CUSP ED),Canadian Journal of Emergency Medicine,2017,10.1017/cem.2017.175,https://experts.mcmaster.ca/display/publication2745905,2025-07-27T15:11:30.476079
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Living systematic review: 1. Introduction—the why, what, when, and how",Journal of Clinical Epidemiology,2017,10.1016/j.jclinepi.2017.08.010,https://experts.mcmaster.ca/display/publication1458320,2025-07-27T15:11:30.476080
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Living systematic reviews: 2. Combining human and machine effort,Journal of Clinical Epidemiology,2017,10.1016/j.jclinepi.2017.08.011,https://experts.mcmaster.ca/display/publication1602430,2025-07-27T15:11:30.476081
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Living systematic reviews: 3. Statistical methods for updating meta-analyses,Journal of Clinical Epidemiology,2017,10.1016/j.jclinepi.2017.08.008,https://experts.mcmaster.ca/display/publication1634040,2025-07-27T15:11:30.476082
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Living systematic reviews: 4. Living guideline recommendations,Journal of Clinical Epidemiology,2017,10.1016/j.jclinepi.2017.08.009,https://experts.mcmaster.ca/display/publication1521416,2025-07-27T15:11:30.476083
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Effectiveness and content analysis of interventions to enhance medication adherence in hypertension: a systematic review and meta-analysis protocol,Systematic Reviews,2016,10.1186/s13643-016-0278-5,https://experts.mcmaster.ca/display/publication459680,2025-07-27T15:11:30.476084
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Identifying Patients With Atrial Fibrillation in Administrative Data,Canadian Journal of Cardiology,2016,10.1016/j.cjca.2016.06.006,https://experts.mcmaster.ca/display/publication459679,2025-07-27T15:11:30.476085
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,The Global Alliance for Chronic Diseases Supports 15 Major Studies in Hypertension Prevention and Control in Low‐ and Middle‐Income Countries,Journal of Clinical Hypertension,2016,10.1111/jch.12835,https://experts.mcmaster.ca/display/publication1721122,2025-07-27T15:11:30.476086
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Mobile Text Messaging and Adherence of Patients to Medication Prescriptions,JAMA Internal Medicine,2016,10.1001/jamainternmed.2015.7853,https://experts.mcmaster.ca/display/publication459681,2025-07-27T15:11:30.476087
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Matching Adherence Interventions to Patient Determinants Using the Theoretical Domains Framework,Frontiers in Pharmacology,2016,10.3389/fphar.2016.00429,https://experts.mcmaster.ca/display/publication459678,2025-07-27T15:11:30.476087
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Behaviour change strategies for reducing blood pressure-related disease burden: findings from a global implementation research programme,Implementation Science,2015,10.1186/s13012-015-0331-0,https://experts.mcmaster.ca/display/publication459682,2025-07-27T15:11:30.476088
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Understanding the modifiable health systems barriers to hypertension management in Malaysia: a multi-method health systems appraisal approach,BMC Health Services Research,2015,10.1186/s12913-015-0916-y,https://experts.mcmaster.ca/display/publication459683,2025-07-27T15:11:30.476089
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Technology-mediated interventions for enhancing medication adherence,Journal of the American Medical Informatics Association : JAMIA,2015,10.1093/jamia/ocu047,https://experts.mcmaster.ca/display/publication459685,2025-07-27T15:11:30.476090
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Patients’ Knowledge, Attitudes, Behaviour and Health Care Experiences on the Prevention, Detection, Management and Control of Hypertension in Colombia: A Qualitative Study",PLoS ONE,2015,10.1371/journal.pone.0122112,https://experts.mcmaster.ca/display/publication459684,2025-07-27T15:11:30.476091
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Tricuspid Valve Regurgitation Following Temporary or Permanent Endocardial Lead Insertion, and the Impact of Cardiac Resynchronization Therapy",Open Cardiovascular Medicine Journal,2014,10.2174/1874192401408010113,https://experts.mcmaster.ca/display/publication459686,2025-07-27T15:11:30.476092
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Interventions for enhancing medication adherence,Cochrane Database of Systematic Reviews,2014,10.1002/14651858.cd000011.pub4,https://experts.mcmaster.ca/display/publication61512,2025-07-27T15:11:30.476093
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey,American Journal of Medicine,2014,10.1016/j.amjmed.2014.05.003,https://experts.mcmaster.ca/display/publication172905,2025-07-27T15:11:30.476094
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Gaps in Medical and Device Therapy for Patients with Left Ventricular Systolic Dysfunction: The EchoGap Study,Open Cardiovascular Medicine Journal,2014,10.2174/1874192401408010094,https://experts.mcmaster.ca/display/publication459687,2025-07-27T15:11:30.476095
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices,Journal of Thrombosis and Thrombolysis,2014,10.1007/s11239-013-0969-x,https://experts.mcmaster.ca/display/publication459691,2025-07-27T15:11:30.476096
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges,European Heart Journal,2014,10.1093/eurheartj/eht407,https://experts.mcmaster.ca/display/publication459689,2025-07-27T15:11:30.476097
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Patient and Healthcare Provider Barriers to Hypertension Awareness, Treatment and Follow Up: A Systematic Review and Meta-Analysis of Qualitative and Quantitative Studies",PLoS ONE,2014,10.1371/journal.pone.0084238,https://experts.mcmaster.ca/display/publication459688,2025-07-27T15:11:30.476098
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Management of dyspepsia symptoms on dabigatran during RELY-ABLE: long-term follow up study after RE-LY,European Heart Journal,2013,10.1093/eurheartj/eht307.p549,https://experts.mcmaster.ca/display/publication3463998,2025-07-27T15:11:30.476099
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Abstract 182: The Impact of National and Regional Health Systems Arrangements on Hypertension Awareness, Treatment and Control: a Systematic Literature Review",Circulation. Cardiovascular Quality and Outcomes,2013,10.1161/circoutcomes.6.suppl_1.a182,https://experts.mcmaster.ca/display/publication3463984,2025-07-27T15:11:30.476100
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Abstract 329: Barriers To Hypertension Screening, Treatment And Control As Reported By Patients And Healthcare Providers",Circulation. Cardiovascular Quality and Outcomes,2013,10.1161/circoutcomes.6.suppl_1.a329,https://experts.mcmaster.ca/display/publication2163856,2025-07-27T15:11:30.476101
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Why are we failing to implement effective therapies in cardiovascular disease?,European Heart Journal,2013,10.1093/eurheartj/ehs481,https://experts.mcmaster.ca/display/publication459692,2025-07-27T15:11:30.476102
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Features of effective computerised clinical decision support systems: meta-regression of 162 randomised trials,The BMJ,2013,10.1136/bmj.f657,https://experts.mcmaster.ca/display/publication175056,2025-07-27T15:11:30.476103
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation,Thrombosis and Haemostasis,2013,10.1160/th12-08-0539,https://experts.mcmaster.ca/display/publication459693,2025-07-27T15:11:30.476104
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"The Influence of Health Systems on Hypertension Awareness, Treatment, and Control: A Systematic Literature Review",PLoS Medicine,2013,10.1371/journal.pmed.1001490,https://experts.mcmaster.ca/display/publication459690,2025-07-27T15:11:30.476105
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Patients originally diagnosed with idiopathic atrial fibrillation more often suffer from insidious coronary artery disease compared to healthy sinus rhythm controls,Heart Rhythm,2012,10.1016/j.hrthm.2012.08.013,https://experts.mcmaster.ca/display/publication459696,2025-07-27T15:11:30.476106
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries,Circulation,2012,10.1161/circulationaha.112.101808,https://experts.mcmaster.ca/display/publication459694,2025-07-27T15:11:30.476107
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Characteristics, management and prognosis of elderly patients in the Euro Heart Survey on atrial fibrillation",Aging - Clinical and Experimental Research,2012,10.1007/bf03654822,https://experts.mcmaster.ca/display/publication3463982,2025-07-27T15:11:30.476108
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Characteristics, management and prognosis of elderly patients in the Euro Heart Survey on atrial fibrillation.",Aging - Clinical and Experimental Research,2012,10.3275/8408,https://experts.mcmaster.ca/display/publication459697,2025-07-27T15:11:30.476109
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study,Thrombosis Research,2012,10.1016/j.thromres.2011.08.024,https://experts.mcmaster.ca/display/publication459700,2025-07-27T15:11:30.476110
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey,Europace,2012,10.1093/europace/eur406,https://experts.mcmaster.ca/display/publication459698,2025-07-27T15:11:30.476111
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort,Europace,2012,10.1093/europace/eur379,https://experts.mcmaster.ca/display/publication459699,2025-07-27T15:11:30.476112
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy,Thrombosis and Haemostasis,2012,10.1160/th12-06-0433,https://experts.mcmaster.ca/display/publication459695,2025-07-27T15:11:30.476113
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Dronedarone in High-Risk Permanent Atrial Fibrillation,New England Journal of Medicine,2011,10.1056/nejmoa1109867,https://experts.mcmaster.ca/display/publication871296,2025-07-27T15:11:30.476154
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Computerized clinical decision support systems for therapeutic drug monitoring and dosing: A decision-maker-researcher partnership systematic review,Implementation Science,2011,10.1186/1748-5908-6-90,https://experts.mcmaster.ca/display/publication459701,2025-07-27T15:11:30.476155
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Abstract P131: Importance of Algorithm-Consistent Warfarin Dosing in the Quality of Anticoagulation Control in Atrial Fibrillation: A Multilevel Analysis,Circulation. Cardiovascular Quality and Outcomes,2011,10.1161/circoutcomes.4.suppl_2.ap131,https://experts.mcmaster.ca/display/publication3463988,2025-07-27T15:11:30.476156
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Abstract P192: The Gap Between Guidelines and Practice for the Total Cardiovascular Care of Atrial Fibrillation Patients in an Extended Study for Re-ly Patients Receiving Dabigatran,Circulation. Cardiovascular Quality and Outcomes,2011,10.1161/circoutcomes.4.suppl_1.ap192,https://experts.mcmaster.ca/display/publication3463989,2025-07-27T15:11:30.476157
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Abstract P199: Randomized Comparison of the DAWN AC Computer Program and a Simple Manual Nomogram for Quality of Warfarin Dosing,Circulation. Cardiovascular Quality and Outcomes,2011,10.1161/circoutcomes.4.suppl_2.ap199,https://experts.mcmaster.ca/display/publication3463987,2025-07-27T15:11:30.476158
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Abstract P200: Computerized Clinical Decision Support Systems for Therapeutic Drug Monitoring and Dosing: A Decision Maker--Researcher Partnership Systematic Review,Circulation. Cardiovascular Quality and Outcomes,2011,10.1161/circoutcomes.4.suppl_2.ap200,https://experts.mcmaster.ca/display/publication3463986,2025-07-27T15:11:30.476159
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Abstract P6: Vitamin K Antagonist Dosing Methods and Individual Patient Quality of INR Control in the International Active W Anticoagulation Study,Circulation. Cardiovascular Quality and Outcomes,2011,10.1161/circoutcomes.4.suppl_2.ap6,https://experts.mcmaster.ca/display/publication3463985,2025-07-27T15:11:30.476160
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Abstract P7: The Impact of Cardiovascular Hospitalization on Mortality and Quality of Life Among 14,261 Atrial Fibrillation Patients in the ACTIVE Study",Circulation. Cardiovascular Quality and Outcomes,2011,10.1161/circoutcomes.4.suppl_2.ap7,https://experts.mcmaster.ca/display/publication3463983,2025-07-27T15:11:30.476161
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients,European Heart Journal,2011,10.1093/eurheartj/ehr226,https://experts.mcmaster.ca/display/publication459702,2025-07-27T15:11:30.476162
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,The burden of atrial fibrillation in the Netherlands,Netherlands Heart Journal,2011,10.1007/s12471-011-0175-4,https://experts.mcmaster.ca/display/publication459703,2025-07-27T15:11:30.476163
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Assessing the Performance of the HAS-BLED Score: Response,Chest,2011,10.1378/chest.11-0184,https://experts.mcmaster.ca/display/publication1080484,2025-07-27T15:11:30.476164
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,The HAS-BLED Score and Renal Failure: Response,Chest,2011,10.1378/chest.10-3237,https://experts.mcmaster.ca/display/publication1080492,2025-07-27T15:11:30.476165
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,The value of cardiovascular hospitalization as an endpoint for clinical atrial fibrillation research,Europace,2011,10.1093/europace/eur119,https://experts.mcmaster.ca/display/publication459704,2025-07-27T15:11:30.476166
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries,Europace,2011,10.1093/europace/euq325,https://experts.mcmaster.ca/display/publication459707,2025-07-27T15:11:30.476167
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Statins Do Not Reduce Atrial Fibrillation After Cardiac Valvular Surgery: A Single Centre Observational Study,Netherlands Heart Journal,2011,10.1007/s12471-010-0055-3,https://experts.mcmaster.ca/display/publication459705,2025-07-27T15:11:30.476168
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Systematic Review to Identify Validated Manual Warfarin Maintenance Dosing Tools.,Blood,2010,10.1182/blood.v116.21.3800.3800,https://experts.mcmaster.ca/display/publication3463990,2025-07-27T15:11:30.476169
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation,Chest,2010,10.1378/chest.10-0134,https://experts.mcmaster.ca/display/publication459709,2025-07-27T15:11:30.476170
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,CHA 2 DS 2 -VASc Risk Scheme: Response,Chest,2010,10.1378/chest.10-0938,https://experts.mcmaster.ca/display/publication1080490,2025-07-27T15:11:30.476171
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Improving guideline adherence in the treatment of atrial fibrillation by implementing an integrated chronic care program,Netherlands Heart Journal,2010,10.1007/bf03091818,https://experts.mcmaster.ca/display/publication459706,2025-07-27T15:11:30.476172
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Lenient rate control is as effective as strict rate control for preventing cardiovascular events in AF,ACP journal club,2010,10.7326/0003-4819-153-4-201008170-02004,https://experts.mcmaster.ca/display/publication459708,2025-07-27T15:11:30.476173
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Obstructive Sleep Apnea Is a Risk Factor for Stroke and Atrial Fibrillation: Response,Chest,2010,10.1378/chest.10-0545,https://experts.mcmaster.ca/display/publication1080493,2025-07-27T15:11:30.476174
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Factors determining utility measured with the EQ-5D in patients with atrial fibrillation,Quality of Life Research,2010,10.1007/s11136-010-9591-y,https://experts.mcmaster.ca/display/publication459711,2025-07-27T15:11:30.476175
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients,Thrombosis Research,2010,10.1016/j.thromres.2009.11.007,https://experts.mcmaster.ca/display/publication175174,2025-07-27T15:11:30.476176
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Progression From Paroxysmal to Persistent Atrial Fibrillation,Journal of the American College of Cardiology,2010,10.1016/j.jacc.2009.11.040,https://experts.mcmaster.ca/display/publication459710,2025-07-27T15:11:30.476177
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach,Chest,2010,10.1378/chest.09-1584,https://experts.mcmaster.ca/display/publication459716,2025-07-27T15:11:30.476178
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Effect of a simple two‐step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study,Journal of Thrombosis and Haemostasis,2010,10.1111/j.1538-7836.2009.03652.x,https://experts.mcmaster.ca/display/publication459712,2025-07-27T15:11:30.476179
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Reply,Journal of the American College of Cardiology,2010,10.1016/j.jacc.2009.09.023,https://experts.mcmaster.ca/display/publication1080486,2025-07-27T15:11:30.476180
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Abstract 5795: Impact of the Modified Henry Ford Warfarin Maintenance Dosing Algorithm on Quality of Anticoagulation at a Specialist Anticoagulation Clinic,Circulation,2009,10.1161/circ.120.suppl_18.s1150-a,https://experts.mcmaster.ca/display/publication3463981,2025-07-27T15:11:30.476181
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Use and Underuse of Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Old and New Paradigms,Seminars in Thrombosis and Hemostasis,2009,10.1055/s-0029-1241048,https://experts.mcmaster.ca/display/publication459714,2025-07-27T15:11:30.476182
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Atrial Fibrillation and Heart Failure in Cardiology Practice: Reciprocal Impact and Combined Management From the Perspective of Atrial Fibrillation,Journal of the American College of Cardiology,2009,10.1016/j.jacc.2009.01.055,https://experts.mcmaster.ca/display/publication459718,2025-07-27T15:11:30.476183
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation,Heart,2009,10.1136/hrt.2008.148528,https://experts.mcmaster.ca/display/publication459722,2025-07-27T15:11:30.476184
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Comprehensive upstream treatment for atrial fibrillation, when and how?",Europace,2009,10.1093/europace/eup050,https://experts.mcmaster.ca/display/publication459720,2025-07-27T15:11:30.476185
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes,Heart,2009,10.1136/hrt.2008.157248,https://experts.mcmaster.ca/display/publication459724,2025-07-27T15:11:30.476186
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation",European Heart Journal,2008,10.1093/eurheartj/ehn139,https://experts.mcmaster.ca/display/publication459726,2025-07-27T15:11:30.476187
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation,Europace,2008,10.1093/europace/eun048,https://experts.mcmaster.ca/display/publication459730,2025-07-27T15:11:30.476188
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?,European Heart Journal,2008,10.1093/eurheartj/ehn101,https://experts.mcmaster.ca/display/publication459728,2025-07-27T15:11:30.476189
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey,European Heart Journal,2008,10.1093/eurheartj/ehn025,https://experts.mcmaster.ca/display/publication459732,2025-07-27T15:11:30.476190
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Atrial fibrillation in the ‘real world’: undecided issues,"European Heart Journal, Supplement",2007,10.1093/eurheartj/sum067,https://experts.mcmaster.ca/display/publication1080459,2025-07-27T15:11:30.476191
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation,American Heart Journal,2007,10.1016/j.ahj.2007.03.008,https://experts.mcmaster.ca/display/publication459736,2025-07-27T15:11:30.476192
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,The Euro Heart Survey Program: What's in It for Nurses?,Progress in Cardiovascular Nursing,2007,10.1111/j.0889-7204.2007.06688.x,https://experts.mcmaster.ca/display/publication459734,2025-07-27T15:11:30.476193
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Gender-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe",Journal of the American College of Cardiology,2007,10.1016/j.jacc.2006.10.047,https://experts.mcmaster.ca/display/publication459738,2025-07-27T15:11:30.476194
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,"Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The Netherlands - The EXAMINE-AF study. A questionnaire survey",International Journal of Clinical Practice,2007,10.1111/j.1742-1241.2006.01241.x,https://experts.mcmaster.ca/display/publication459740,2025-07-27T15:11:30.476195
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation,European Heart Journal,2006,10.1093/eurheartj/ehl015,https://experts.mcmaster.ca/display/publication459742,2025-07-27T15:11:30.476196
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population,European Heart Journal,2006,10.1093/eurheartj/ehl193,https://experts.mcmaster.ca/display/publication1939644,2025-07-27T15:11:30.476197
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Sustained benefit 20 years after reperfusion therapy in acute myocardial infarction,Journal of Emergency Medicine,2006,10.1016/j.jemermed.2005.11.026,https://experts.mcmaster.ca/display/publication3463996,2025-07-27T15:11:30.476198
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Which Factors Are Associated with the Application of Reperfusion Therapy in ST-Elevation Acute Coronary Syndromes?,Cardiology,2006,10.1159/000092768,https://experts.mcmaster.ca/display/publication459744,2025-07-27T15:11:30.476199
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Atrial fibrillation management: a prospective survey in ESC Member Countries,European Heart Journal,2005,10.1093/eurheartj/ehi505,https://experts.mcmaster.ca/display/publication459746,2025-07-27T15:11:30.476200
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Sustained Benefit 20 Years After Reperfusion Therapy in Acute Myocardial Infarction,ACC Cardiosource Review Journal,2005,10.1016/j.accreview.2005.09.012,https://experts.mcmaster.ca/display/publication3463997,2025-07-27T15:11:30.476201
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Sustained Benefit 20 Years After Reperfusion Therapy in Acute Myocardial Infarction,Journal of the American College of Cardiology,2005,10.1016/j.jacc.2005.03.047,https://experts.mcmaster.ca/display/publication459748,2025-07-27T15:11:30.476202
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,The prevalence of abnormal glucose regulation in patients with coronary artery disease across EuropeThe Euro Heart Survey on diabetes and the heart,European Heart Journal,2004,10.1016/j.ehj.2004.07.027,https://experts.mcmaster.ca/display/publication1939646,2025-07-27T15:11:30.476203
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,[Treatment of patients with acute coronary syndromes in the Netherlands in 2000-2001; a comparison with other European countries and with the guidelines].,Nederlands Tijdschrift voor Geneeskunde,2004,,https://experts.mcmaster.ca/display/publication459750,2025-07-27T15:11:30.476204
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,1313: Management of ST-Elevation Acute Coronary Syndrome Patients. A Nurses' View on the Euro Heart Survey on Acute Coronary Syndromes,European Journal of Cardiovascular Nursing,2004,10.1017/147451510400300115,https://experts.mcmaster.ca/display/publication3463991,2025-07-27T15:11:30.476205
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,1369: Quality of Life in Patients With Established Coronary Heart Disease: Results from the Euro Heart Survey on Coronary Revascularization (EHS-CR),European Journal of Cardiovascular Nursing,2004,10.1017/147451510400300170,https://experts.mcmaster.ca/display/publication3463992,2025-07-27T15:11:30.476206
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Continuously improving the practice of cardiology.,Netherlands Heart Journal,2004,,https://experts.mcmaster.ca/display/publication459752,2025-07-27T15:11:30.476207
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Increased uncoupling protein 3 content does not affect mitochondrial function in human skeletal muscle in vivo,Journal of Clinical Investigation,2003,10.1172/jci16653,https://experts.mcmaster.ca/display/publication459754,2025-07-27T15:11:30.476207
Robby Nieuwlaat,nieuwlr@mcmaster.ca,journal_articles,Increased uncoupling protein 3 content does not affect mitochondrial function in human skeletal muscle in vivo,Journal of Clinical Investigation,2003,10.1172/JCI16653,https://experts.mcmaster.ca/display/publication1080491,2025-07-27T15:11:30.476208
Robby Nieuwlaat,nieuwlr@mcmaster.ca,chapters,Clinical barriers to the use of recommended stroke prevention therapy,,2012,10.2217/ebo.12.138,https://experts.mcmaster.ca/display/publication1939645,2025-07-27T15:11:30.476210
Robby Nieuwlaat,nieuwlr@mcmaster.ca,chapters,Clinical barriers to the use of recommended stroke prevention therapy,,2012,10.2217/ebo.12.138,https://experts.mcmaster.ca/display/publication2126278,2025-07-27T15:11:30.476211
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,"PATIENT SELECTION, REGION AND TREATING PHYSICIAN ARE RELATED TO ESTIMATES OF ORAL ANTICOAGULATION USE IN ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS",Journal of the American College of Cardiology,2020,10.1016/s0735-1097(20)30952-9,https://experts.mcmaster.ca/display/publication1813274,2025-07-27T15:11:30.476212
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,When are atrial fibrillation patients at risk to discontinue anticoagulation treatment? Results from the GLORIA-AF Registry,European Heart Journal,2018,,https://experts.mcmaster.ca/display/publication1634639,2025-07-27T15:11:30.476213
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Epidemiological Trends in Atrial Fibrillation in Europe: The EURObservational Research Programme in Atrial Fibrillation Pilot and Long-Term Registries and Euro Heart Survey on Atrial Fibrillation,Circulation,2017,,https://experts.mcmaster.ca/display/publication3463979,2025-07-27T15:11:30.476214
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Scope and Consistency of Adherence Related Outcomes in Randomized Controlled Trials of Interventions for Improving Medication Adherence,Arthritis & Rheumatology,2017,,https://experts.mcmaster.ca/display/publication1473419,2025-07-27T15:11:30.476215
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Changes in thromboembolic risk profile and antithrombotic therapy use over a decade: a comparison of Euro Heart Survey on AF and EURObservational research programme AF pilot registry,European Heart Journal,2017,,https://experts.mcmaster.ca/display/publication1624740,2025-07-27T15:11:30.476216
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,PERSISTENCE WITH THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION: THE GLORIA-AF REGISTRY,Journal of the American College of Cardiology,2017,10.1016/s0735-1097(17)33763-4,https://experts.mcmaster.ca/display/publication1080444,2025-07-27T15:11:30.476217
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Progression to asymptomatic atrial fibrillation as a prognostic index: the Euro Heart Study,European Heart Journal,2015,,https://experts.mcmaster.ca/display/publication1080479,2025-07-27T15:11:30.476218
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Management of dyspepsia symptoms on dabigatran during RELY-ABLE: a long-term follow up of RE-LY patients.,Pharmacotherapy,2014,,https://experts.mcmaster.ca/display/publication1080478,2025-07-27T15:11:30.476219
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Echocardiographic Assessment of Tricuspid Valve Regurgitation Induced by Temporary or Permanent Leads in Patients Undergoing Ablation or Permanent Device Implantation,Canadian Journal of Cardiology,2013,10.1016/j.cjca.2013.07.238,https://experts.mcmaster.ca/display/publication978827,2025-07-27T15:11:30.476219
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Management of dyspepsia symptoms on dabigatran during RELY-ABLE: long-term follow up study after RE-LY,European Heart Journal,2013,,https://experts.mcmaster.ca/display/publication651904,2025-07-27T15:11:30.476220
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Cluster Randomized Controlled Trial to Test The Effect of a Multifaceted Comprehensive Cardiovascular Care Intervention on Clinical Outcomes in Atrial Fibrillation Patients Receiving Dabigatran,Circulation,2012,,https://experts.mcmaster.ca/display/publication639837,2025-07-27T15:11:30.476221
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,902 Cluster Randomized Controlled Trial to Test the Effect of Computer-Generated Individualized Audit and Feedback to Patients and Physicians on Clinical Outcomes in Atrial Fibrillation Patients Participating in a Large Multi-Center Trial of Dabigatran,Canadian Journal of Cardiology,2012,10.1016/j.cjca.2012.07.742,https://experts.mcmaster.ca/display/publication639918,2025-07-27T15:11:30.476222
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Net clinical benefit of apixaban among patients with atrial fibrillation,European Heart Journal,2012,,https://experts.mcmaster.ca/display/publication1080470,2025-07-27T15:11:30.476223
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Effect of dronedarone in patients with permanent atrial fibrillation during the ATHENA study,European Heart Journal,2011,,https://experts.mcmaster.ca/display/publication1080475,2025-07-27T15:11:30.476224
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Importance of algorithm-based warfarin dosing in the quality of anticoagulation control in atrial fibrillation - a multilevel analysis,European Heart Journal,2011,,https://experts.mcmaster.ca/display/publication998019,2025-07-27T15:11:30.476225
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Randomized comparison of the DAWN AC computer program and a simple manual nomogram for quality of warfarin dosing,Journal of Thrombosis and Haemostasis,2011,,https://experts.mcmaster.ca/display/publication593696,2025-07-27T15:11:30.476226
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Vitamin K antagonist dosing methods and individual patient quality of INR control in the international active W anticoagulation study,Journal of Thrombosis and Haemostasis,2011,,https://experts.mcmaster.ca/display/publication1080477,2025-07-27T15:11:30.476227
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Systematic Review to Identify Validated Manual Warfarin Maintenance Dosing Tools,Blood,2010,,https://experts.mcmaster.ca/display/publication593902,2025-07-27T15:11:30.476228
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,A novel user-friendly score to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro HeartSurvey,European Heart Journal,2010,,https://experts.mcmaster.ca/display/publication1080488,2025-07-27T15:11:30.476229
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Impact of the Modified Henry Ford Warfarin Maintenance Dosing Algorithm an Quality of Anticoagulation at a Specialist Anticoagulation Clinic,Circulation,2009,,https://experts.mcmaster.ca/display/publication711408,2025-07-27T15:11:30.476230
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,"A simple, new risk factor based approach to refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation: The Euro Heart Survey on atrial fibrillation",European Heart Journal,2009,,https://experts.mcmaster.ca/display/publication1080480,2025-07-27T15:11:30.476231
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,"Euro heart survey on AF: costs of Atrial Fibrillation (AF) for ATHENA-like patients in Greece, Italy, Poland, Spain and the Netherlands",European Heart Journal,2009,,https://experts.mcmaster.ca/display/publication1080476,2025-07-27T15:11:30.476232
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Female gender and vascular disease are true risk factors for stroke in patients with atrial fibrillation: data from the Euro Heart Survey,European Heart Journal,2009,,https://experts.mcmaster.ca/display/publication1080469,2025-07-27T15:11:30.476233
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Progression from paroxysmal atrial fibrillation to more sustained forms: clinical correlates and therapeutical consequences,European Heart Journal,2009,,https://experts.mcmaster.ca/display/publication1080472,2025-07-27T15:11:30.476234
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Validation of contemporary risk stratification schema for predicting stroke and thromboembolism in real world atrial fibrillation patients from the Euro Heart Survey on Atrial Fibrillation,European Heart Journal,2009,,https://experts.mcmaster.ca/display/publication1080473,2025-07-27T15:11:30.476235
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,"Underuse of Evidence Based Methods for Management of Warfarin in Atrial Fibrillation Patients in Hamilton, Canada",Journal of the American College of Cardiology,2009,,https://experts.mcmaster.ca/display/publication1080495,2025-07-27T15:11:30.476236
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,"Improved anti-thrombotic therapy in a guidelines-based, nurse-driven, ICT-supported disease management program for patients in atrial fibrillation",Acta Cardiologica,2009,,https://experts.mcmaster.ca/display/publication1080489,2025-07-27T15:11:30.476237
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,PCV93 FACTORS DETERMINING UTILITY MEASURED WITHTHE EQ-5D IN PATIENTS WITH A TRIAL FIBRILLATION,Value in Health,2008,10.1016/s1098-3015(10)66391-7,https://experts.mcmaster.ca/display/publication1080485,2025-07-27T15:11:30.476238
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Autonomic trigger patterns and anti-arrhythmic treatment of atrial fibrillation: data from the Euro Heart Survey,European Heart Journal,2007,,https://experts.mcmaster.ca/display/publication1080474,2025-07-27T15:11:30.476239
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,856 The impact of heart failure on the characteristics and management of atrial fibrillation patients,"European Journal of Heart Failure, Supplement",2007,10.1016/s1567-4215(07)60523-2,https://experts.mcmaster.ca/display/publication1080450,2025-07-27T15:11:30.476240
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Guideline adherent antithrombotic treatment is associated with improved cardiovascular outcome compared to undertreatment in real-life atrial fibrillation patients at high risk for stroke,Circulation,2006,,https://experts.mcmaster.ca/display/publication1080435,2025-07-27T15:11:30.476241
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Should we abandon the paradigm of withholding oral anticoagulation in paroxysmal atrial fibrillation?,Circulation,2006,,https://experts.mcmaster.ca/display/publication1080436,2025-07-27T15:11:30.476242
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,"Antithrombotic drug prescription and its rationale among general practitioners, internal medicine specialists and cardiologists in The Netherlands. The EXAMINE-AF study",European Heart Journal,2006,,https://experts.mcmaster.ca/display/publication1080439,2025-07-27T15:11:30.476243
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Guideline adherent antithrombotic treatment is associated with improved outcome compared to undertreatment in real life atrial fibrillation patients,European Heart Journal,2006,,https://experts.mcmaster.ca/display/publication1080447,2025-07-27T15:11:30.476244
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,The cost of atrial fibrillation management in Europe: a cross-sectional study on resource use during admissions and outpatient clinic visits in the Euro Heart Survey cohort,European Heart Journal,2006,,https://experts.mcmaster.ca/display/publication1080455,2025-07-27T15:11:30.476245
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,The oldest old patients have a lower chance for receiving guidelines recommended atrial fibrillation therapy. The experience of the Euro Heart Survey on atrial fibrillation,Journal of the American College of Cardiology,2006,,https://experts.mcmaster.ca/display/publication1080442,2025-07-27T15:11:30.476246
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Patients with atrial fibrillation induced tachycardiomyopathy are at high risk for stroke,Circulation,2005,,https://experts.mcmaster.ca/display/publication1080440,2025-07-27T15:11:30.476247
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Vagal and adrenergic atrial fibrillation is found frequently among patients in the Euro Heart Survey,European Heart Journal,2005,,https://experts.mcmaster.ca/display/publication1080457,2025-07-27T15:11:30.476248
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Which factors determine oral anticoagulation prescription in real life atrial fibrillation patients?,European Heart Journal,2005,,https://experts.mcmaster.ca/display/publication1080434,2025-07-27T15:11:30.476249
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,Women with atrial fibrillation are less aggressively treated than men,European Heart Journal,2005,,https://experts.mcmaster.ca/display/publication1080438,2025-07-27T15:11:30.476250
Robby Nieuwlaat,nieuwlr@mcmaster.ca,conferences,2055 Which factors determine the application of reperfusion therapy in ST-elevation acute coronary syndromes? Lessons from the Euro-Heart acute coronary syndromes survey,European Heart Journal,2003,10.1016/s0195-668x(03)95052-4,https://experts.mcmaster.ca/display/publication1080487,2025-07-27T15:11:30.476251
